HIV-1 evolutionary dynamics under non-suppressive antiretroviral therapy - Kemp, Steven A.; Charles, Oscar; Derache, Anne; Iwuji, Collins; Adamson, John; Govender, Katya; de Oliveira, Tulio; Okesola, Nonhlanhla; Dabis, Francois; Martin, Darren P.; on behalf of the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group; Pillay, Deenan; et al. (medRxiv, 2021)
Prolonged virologic failure on 2nd-line protease inhibitor (PI) based ART without emergence of major protease mutations is well recognised and provides an opportunity to study within-host evolution in long-term viraemic individuals. Using next-generation sequencing and in silico haplotype reconstruction we analysed whole genome sequences from longitudinal plasma samples of eight chronically infected HIV-1 individuals failing 2nd-line regimens from the ANRS 12249 TasP trial. On non-suppressive ART, there were large fluctuations in synonymous and non-synonymous variant frequencies despite stable viraemia. Reconstructed haplotypes provided evidence for selective sweeps during periods of partial adherence, and viral haplotype competition during periods of low drug exposure. Drug resistance mutations in reverse transcriptase (RT) from earlier and current ART were used as markers of viral haplotypes in the reservoir and their distribution over time indicated recombination. We independently observed linkage disequilibrium decay, indicative of recombination. These data highlight dramatic changes in virus population structure that occur during stable viremia under non suppressive ART.Competing Interest StatementRKG has received ad hoc consulting fees from Gilead, ViiV and UMOVIS Lab.Clinical TrialClinicaltrials.gov: NCT01509508Funding StatementSAK is supported by the Bill and Melinda Gates Foundation: OPP1175094. RKG is supported by Wellcome Trust Senior Fellowship in Clinical Science: WT108082AIA. DPM is funded by The Wellcome Trust (222574/Z/21/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was originally grant by the Biomedical Research Ethics Committee (BFC 104/11) at the University of KwaZulu-Natal, and the Medicines Control Council of South Africa for the TasP trial (Clinicaltrials.gov: NCT01509508; South African Trial Register: DOH-27-0512-3974). The study was also authorized by the KwaZulu-Natal Department of Health in South Africa. Written informed consent was obtained from all participants. Original ethical approval also included downstream sequencing of blood plasma samples and analysis of those sequences to better understand drug resistance. No additional ethical approval was required for this.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data has been provided as supplementary tables. Sequencing data can be provided upon reasonable request to the authors.